NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
McDonagh MS, Peterson K, Carson S, et al. Drug Class Review: Atypical Antipsychotic Drugs: Final Report Update 2 [Internet]. Portland, (OR): Oregon Health & Science University; 2008 Jun.
This publication is provided for historical reference only and the information may be out of date.
Drug Class Review: Atypical Antipsychotic Drugs: Final Report Update 2 [Internet].
Show details1= Study was published in a language other than English
2= Outcome was not included in the scope of this review
3= Drug was not included in the scope of this review
4= Study population was not included in the scope of this review (e.g., pediatric for bipolar I disorder or schizophrenia)
5= Publication type (e.g. letter, case report) was not included in the scope of this review
6= Study design was not included in the scope of this review (e.g., dose ranging study, pharmacokinetics)
7= Study duration did not meet the criteria for this review
8= Study not found in library searches
AUTHOR | YEAR | Journal of Publication | Reason for Exclusion |
---|---|---|---|
Addington | 1997 | Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie | 5 |
Ahluwalia | 2002 | National Research Register | 5 |
Ahmed | 2003 | Schizophrenia Research | 5 |
Aleman | 2001 | European Neuropsychopharmacology | 6 |
Allison | 2001 | Journal of Clinical Psychiatry | 5 |
Anderson | 1993 | Pharmacotherapy | 6 |
Andrade | 2004 | American Journal of Psychiatry | 5 |
Anonymous | 1999 | Lancet | 4 |
Anonymous | 1999 | New England Journal of Medicine | 4 |
Anonymous | 2003 | Clinical Trials Journal | 9 |
Arango | 2003 | American Journal of Psychiatry | 2 |
Arango | 2003 | American Journal of Psychiatry | 2 |
Arranz | 1996 | Neuroscience Letters | 2 |
Arranz | 1998 | Schizophrenia Research | 2 |
Bai | 1999 | Psychiatric Services | 4 |
Bailey | 1997 | Psychopharmacology Bulletin | 3 |
Baker | 2003 | Journal of Affective Disorders | 5 |
Baldacchino | 1994 | Pharmaceutical Journal | 6 |
Bandelow | 1992 | European Archives of Psychiatry & Clinical Neuroscience | 6 |
Barzman | 2004 | Journal of Child & Adolescent Psychopharmacology | 4 |
Basson | 2001 | Journal of Clinical Psychiatry | 5 |
Beasley | 1999 | British Journal of Psychiatry | 6 |
Beasley | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Beasley | 1996 | Psychopharmacology | 4 |
Beasley | 1997 | Journal of Clinical Psychiatry | 5 |
Benattia | 2003 | Schizophrenia Research | 5 |
Beuzen | 1998 | 11th Congress of The European College of Neuropsychopharmacology | 5 |
Beuzen | 1999 | 11th World Congress of Psychiatry | 1 |
Blumensohn | 1998 | International Clinical Psychopharmacology | 4 |
Bogan | 2000 | Progress in Neuro-Psychopharmacology & Biological Psychiatry | 2 |
Bonanno | 2001 | Annals of Pharmacotherapy | 6 |
Bondolfi | 1996 | European Neuropsychopharmacology | 5 |
Borison | 1991 | Clinical report | 5 |
Bouchard | 2002 | Encephale | 1 |
Breier | 2003 | Schizophrenia Research | 5 |
Briken | 2002 | Schizophrenia Research | 4 |
Britto | 2002 | National Research Register | 5 |
Brook | 2002 | XIIth World Congress of Psychiatry | 1 |
Brook | 2002 | Journal of the European College of Neuropsychopharmacology | 5 |
Buckley | 1994 | Journal of Clinical Psychiatry | 6 |
Busch | 2004 | Archives of General Psychiatry | 3 |
Butler | 2000 | International Journal of Psychiatry in Clinical Practice | 3 |
Byerly | 1999 | Stanley Foundation Research Awards | 5 |
Byne | 2000 | International Journal of Geriatric Psychiatry | 6 |
Callaghan | 1997 | Journal of Clinical Pharmacology | 4 |
Cao | 2003 | Chinese Journal of Medicine Research | 1 |
Carlson | 2003 | Journal of Clinical Psychiatry | 6 |
Carter | 1995 | Psychopharmacology Bulletin | 3 |
Cassidy | 1999 | American Journal of Psychiatry | 3 |
Chae | 2001 | Human Psychopharmacology | 2 |
Chan | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Chaudhry | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Chengappa | 1999 | Journal of Clinical Psychiatry | 2 |
Chengappa | 2003 | Bipolar Disorders | 6 |
Chiu | 2002 | XIIth World Congress of Psychiatry | 1 |
Chouinard | 1994 | Progress in Neuro-Psychopharmacology & Biological Psychiatry | 6 |
Citrome | 2004 | Psychiatric Services | 6 |
Clark | 2002 | Schizophrenia Bulletin | 3 |
Cohen | 1990 | American Journal of Psychiatry | 6 |
Conley | 2000 | Biological Psychiatry | 5 |
Corrigan | 2004 | Biological Psychiatry | 3 |
Corripio | 2005 | Progress in Neuro-Psychopharmacology & Biological Psychiatry | 3 |
Cramer | 2001 | Schizophrenia Bulletin | 2 |
Csernansky | 1999 | XI World Congress of Psychiatry, Hamburg, August | 1 |
Csernansky | 1999 | 11th World Congress of Psychiatry | 1 |
Daniel | 1998 | Psychopharmacology Bulletin | 3 |
Davidson | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Delassus-Guenault | 1999 | Journal of Clinical Pharmacy & Therapeutics | 6 |
Drake | 2000 | Schizophrenia Bulletin | 2 |
Dyck | 2000 | Psychiatric Services | 6 |
Ebenbichler | 2003 | Journal of Clinical Psychiatry | 4 |
Edgar | 2002 | Schizophrenia Research | 2 |
Ellis | 2000 | Journal of Neuropsychiatry & Clinical Neurosciences | 4 |
Ernst | 2004 | Harvard Review of Psychiatry | 5 |
Fabre | 1995 | Clinical Therapeutics | 6 |
Facciola | 1999 | Therapeutic Drug Monitoring | 6 |
Factor | 2001 | Movement Disorders | 4 |
Farren | 2000 | Drug & Alcohol Dependence | 6 |
Fleurot | 2002 | XIIth World Congress of Psychiatry | 1 |
Frazier | 1999 | Journal of the American Academy of Child & Adolescent Psychiatry | 4 |
Gagiano | 2000 | International Journal of Neuropsychopharmacology Abstracts of the XXIInd CINP Congress, Brussels, Belgium, July 9–13 | 5 |
Gallhofer | 1996 | European Neuropsychopharmacology | 6 |
George | 2001 | National Research Register | 5 |
George | 2002 | Archives of General Psychiatry | 2 |
Gitlin | 2001 | American Journal of Psychiatry | 3 |
Glazer | 2004 | Jama | 2 |
Glazer | 2000 | Journal of Clinical Psychiatry | 5 |
Goetz | 2000 | Neurology | 4 |
Goldberg | 2000 | Psychological Medicine | 2 |
Goldstein | 1999 | Psychosomatics | 6 |
Greenspan | 2002 | CMAJ Canadian Medical Association Journal | 6 |
Hagg | 2000 | Lancet | 5 |
Hamelin | 1999 | Pharmacotherapy | 6 |
Harvey | 2001 | International Drug Therapy Newsletter | 5 |
Heinz | 1998 | Schizophrenia Research | 4 |
Henderson | 2001 | Journal of Clinical Psychiatry | 6 |
Henderson | 1998 | Journal of Clinical Psychiatry | 6 |
Herrera | 1988 | Schizophrenia Research | 6 |
Hertling | 2003 | Psychopharmakotherapie | 1 |
Holmes | 2004 | National Research Register | 5 |
Hummer | 1996 | Psychopharmacology | 4 |
Huo | 2003 | Medical Journal of Chinese Civil Administratio | 1 |
Hutton | 2002 | Journal of Neurology, Neurosurgery & Psychiatry | 2 |
Huttunen | 1994 | European Psychiatry | 5 |
Inada | 2003 | International Clinical Psychopharmacology | 5 |
Jeste | 2001 | International Psychogeriatrics | 5 |
Jiaxiu | 2003 | Chinese Mental Health Journal | 1 |
Jin | 2002 | Annals of Clinical Psychiatry | 6 |
Jones | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Joy | 2004 | Cochrane Library | 3 |
Kando | 1997 | Annals of Pharmacotherapy | 5 |
Kang | 2000 | Journal of Clinical Psychiatry | 6 |
Keefe | 2003 | Psychopharmacology | 2 |
Kerepcic | 1994 | Psychiatria Danubina | 6 |
Kimmel | 1994 | Journal of Clinical Psychiatry | 5 |
King | 2002 | XIIth World Congress of Psychiatry | 1 |
Kinon | 2003 | Psychoneuroendocrinology | 3 |
Klieser | 1996 | Serotonin in Antipsychotic Treatment Mechanisms and Clinical Practice | 6 |
Kopala | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Kostic | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Koval | 1994 | American Journal of Psychiatry | 6 |
Lacey | 1995 | American Journal of Psychiatry | 6 |
Lavalaye | 1999 | Psychiatry Research | 6 |
Lee | 1994 | Journal of Clinical Psychiatry | 5 |
Leonard | 2002 | Irish Medical Journal | 6 |
Lieberman | 2001 | Computer Retrieval of Information on Scientific Projects | 4 |
Lin | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Link | 1995 | 8th Congress of the European College of Neuropsychopharmacology | 5 |
Lloyd | 2002 | National Research Register | 5 |
Loebel | 2004 | CNS Spectrums | 5 |
Malykhin | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Marder | 1992 | Clinical Neuropharmacology | 5 |
Martenyi | 2001 | Journal of Clinical Psychiatry | 6 |
McDougle | 1997 | Journal of the American Academy of Child & Adolescent Psychiatry | 7 |
McEvoy | 1994 | Journal of Clinical Psychiatry | 5 |
McQuade | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
McQuade | 2003 | Schizophrenia Research | 5 |
Meco | 1995 | Human Psychopharmacology | 4 |
Meltzer | 2002 | European Psychiatry | 5 |
Meltzer | 2002 | Current Psychiatry Reports | 5 |
Meltzer | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Meltzer | 1999 | Schizophrenia Bulletin | 5 |
Mojtabai | 2003 | Schizophrenia Bulletin | 6 |
Monnelly | 2003 | Journal of Clinical Psychopharmacology | 4 |
Montgomery | 2003 | Schizophrenia Research | 5 |
Mortimer | 2002 | National Research Register | 5 |
Mortimer | 2002 | National Research Register | 5 |
Mortimer | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Mortimer | 1997 | Human Psychopharmacology | 6 |
Naber | 1998 | International Clinical Psychopharmacology | 6 |
Namjoshi | 2003 | Schizophrenia Research | 5 |
Nasrallah | 2004 | American Journal of Geriatric Psychiatry | 3 |
Opolka | 2003 | Journal of Clinical Psychiatry | 2 |
Owens | 1998 | Evidence-Based Mental Health | 5 |
Palazidou | 2002 | National Research Register | 5 |
Pallanti | 1999 | Psychiatry Research | 2 |
Pallanti | 1997 | American Journal of Psychiatry | 6 |
Perez | 2003 | Schizophrenia Research | 5 |
Peuskens | 2002 | European Neuropsychopharmacology | 5 |
Philipp | 2002 | Psychopharmakotherapie | 1 |
Purdon | 2003 | Psychopharmacology | 2 |
Rabinowitz | 2001 | Schizophrenia Bulletin | 2 |
Rabinowitz | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Raja | 2000 | General Hospital Psychiatry | 6 |
Ray | 2001 | Archives of General Psychiatry | 3 |
Reimherr | 2001 | APA Institute on Psychiatric Services, October10–14,2001, Orlando, FL | 4 |
Reynolds | 2002 | National Research Register | 5 |
Reznik | 2004 | Pharmacopsychiatry | 6 |
Robinson | 1999 | Archives of General Psychiatry | 3 |
Rosebush | 2000 | Stanley Foundation Research Awards | 5 |
Rosenheck | 2000 | Journal of Clinical Psychiatry | 6 |
Ruths | 2004 | Journal of the American Geriatrics Society | 6 |
Saari | 2004 | Journal of Clinical Psychiatry | 6 |
Sacchetti | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Samuel | 2003 | Journal of Mental Health | 6 |
Schneider | 2003 | American Journal of Geriatric Psychiatry | 2 |
Schooler | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Schooler | 1994 | Journal of Clinical Psychiatry | 5 |
Sernyak | 2003 | Journal of Clinical Psychiatry | 2 |
Shi | 2004 | Current Medical Research & Opinion | 6 |
Simpson | 2002 | European Psychiatry | 5 |
Simpson | 1999 | 51st Institute on Psychiatric Services | 5 |
Simpson | 2002 | Journal of the European College of Neuropsychopharmacology | 5 |
Simpson | 2003 | Schizophrenia Research | 6 |
Skelton | 1995 | Experimental & Clinical Psychopharmacology | 5 |
Small | 2004 | Current Medical Research & Opinion | 6 |
Stankovska | 2002 | XIIth World Congress of Psychiatry | 1 |
Stock | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Suppes | 2004 | Bipolar Disorders | 2 |
Svestka | 1990 | Activitas Nervosa Superior | 5 |
Svestka | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Svestka | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Sweeney | 1997 | Neuropsychopharmacology | 2 |
Taneli | 2003 | Journal of the European College of Neuropsychopharmacology | 5 |
Tatossian | 1991 | Clinical report | 9 |
Tohen | 2005 | Bipolar Disorders | 5 |
Tohen | 2001 | Journal of Affective Disorders | 3 |
Turner | 2002 | National Research Register | 5 |
Van Dijk | 1998 | British Journal of Clinical Pharmacology | 3 |
Vieta | 2004 | Journal of Clinical Psychiatry | 6 |
Walker | 1997 | Epidemiology | 7 |
Wang | 2002 | Chinese Journal of Pharmacoepidemiology | 1 |
Weickert | 2003 | Neuropsychopharmacology | 6 |
Weiden | 2002 | European Psychiatry | 5 |
Weiser | 2002 | International Journal of Geriatric Psychiatry | 3 |
Wetterling | 2001 | Drug Safety | 5 |
Wilson | 2002 | Schizophrenia Research | 7 |
Wilton | 2001 | Journal of Psychopharmacology | 3 |
Wirshing | 2003 | Psychiatric Clinics of North America | 5 |
Wong | 2001 | Journal of Clinical Psychopharmacology | 6 |
Wooltorton | 2002 | CMAJ Canadian Medical Association Journal | 5 |
Yang | 2002 | Herald of Medicine | 1 |
Yang | 2003 | Archives of Psychiatry | 5 |
Yeung | 2001 | European Neuropsychopharmacology | 5 |
Zahn | 1993 | Biological Psychiatry | 6 |
Zahn | 1994 | Schizophrenia Research | 6 |
Zarate | 1995 | Journal of Clinical Psychiatry | 2 |
Zhang | 2003 | The Chinese Journal of Clinical Pharmacology | 1 |
Zhao | 2003 | Schizophrenia Research | 5 |
Zhou | 2002 | The Chinese Journal of Clinical Pharmacology | 1 |
Zornberg | 2000 | Lancet | 4 |
Excluded Studies Update 2
Active-control trials | ||
1 | Brook S, Walden J, Benattia I, Siu CO, Romano SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology. Apr 2005;178(4):514–523. | 2 |
2 | Buchanan RW, Ball MP, Weiner E, et al. Olanzapine treatment of residual positive and negative symptoms. American Journal of Psychiatry. Jan 2005;162(1):124–129. | 2 |
3 | Correia Filho AG, Bodanese R, Silva TL, Alvares JP, Aman M, Rohde LA. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. Journal of the American Academy of Child & Adolescent Psychiatry. Aug 2005;44(8):748–755. | 2 |
4 | Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. International Journal of Neuropsychopharmacology. Jun 2005;8(2):175–182. | 2 |
5 | Glick ID, Marder SR. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry. May 2005;66(5):638–641. | 2 |
6 | Good KP, Rabinowitz J, Whitehorn D, Harvey PD, DeSmedt G, Kopala LC. The relationship of neuropsychological test performance with the PANSS in antipsychotic naive, first-episode psychosis patients. Schizophrenia Research. May 1 2004;68(1):11–19. | 2 |
7 | Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. American Journal of Psychiatry. Oct 2005;162(10):1888–1895. | 2 |
8 | Houston JP, Lipkovich IA, Ahl J, Rotelli MD, Baker RW, Bowden CL. Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium. Journal of Psychiatric Research. Oct 2007;41(7):616–621. | 2 |
9 | Jakovljevic M, Pivac N, Mihaljevic-Peles A, et al. The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. Mar 30 2007;31(2):399–402. | 2 |
10 | Remillard S, Pourcher E, Cohen H. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. Schizophrenia Research. Dec 1 2005;80(1):99–106. | 2 |
11 | Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie. Jul 2006;51(8):531–539. | 2 |
12 | Emsley R, Rabinowitz J, Medori R, Early Psychosis Global Working G. Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. Schizophrenia Research. Jan 2007;89(1–3):129–139. | 3 |
13 | Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clinical Neuropharmacology. Nov–Dec 2006;29(6):331–337. | 4 |
14 | Rubio G, Martinez-Gras I, Ponce G, et al. Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a longterm controlled study. The Journal of the European College of Neuropsychopharmacology. Vol. 2005;15(3). | 5 |
15 | Citrome L, Volavka J, Czobor P, Brook S, Loebel A, Mandel FS. Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. Journal of Clinical Psychiatry. Apr 2006;67(4):638–642. | 6 |
16 | Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. International Clinical Psychopharmacology. 2000;15(3):121–131. | 6 |
17 | Lecrubier Y, Quintin P, Bouhassira M, Perrin E, Lancrenon S. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatrica Scandinavica. Nov 2006;114(5):319–327. | 6 |
18 | Lim H-K, Pae C-U, Lee C, Lee C-U. Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomized, open, prospective study. Neuropsychobiology. 2006;54(4):247–251. | 6 |
19 | Lindenmayer J-P, Khan A, Iskander A, Abad MT, Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. Journal of Clinical Psychiatry. Mar 2007;68(3):368–379. | 6 |
20 | Olie J-P, Spina E, Murray S, Yang R. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. International Clinical Psychopharmacology. May 2006;21(3):143–151. | 6 |
21 | Tandon R, al e. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial with Aripiprazole (BETA). Schizophrenia Research. 2006:77–89. | 6 |
22 | Ownby RL. Quetiapine and rivastigmine for agitation in Alzheimer's disease. Current Psychiatry Reports. Feb 2006;8(1):10. | 8 |
Head-to-head trials | ||
23 | Gharabawi GM, Greenspan A, Rupnow MFT, et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry. 2006;6:45. | 2 |
24 | Harvey PD, Bowie CR, Loebel A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine. Journal of Neuropsychiatry & Clinical Neurosciences. 2006;18(1):54–63. | 2 |
25 | McGurk SR, Carter C, Goldman R, et al. The effects of clozapine and risperidone on spatial working memory in schizophrenia. American Journal of Psychiatry. May 2005;162(5):1013–1016. | 2 |
26 | Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry. Dec 2006;163(12):2080–2089. | 2 |
27 | Ryan MCM, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia.1. Life Sciences. Mar 5 2004;74(16):1999–2008. | 2 |
28 | Lewis SW, Barnes TRE, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin. Oct 2006;32(4):715–723. | 3 |
29 | Kraus JE, Sheitman BB, Cook A, Reviere R, Lieberman JA. Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. Journal of Clinical Psychiatry. Dec 2005;66(12):1564–1568. | 4 |
30 | McClellan J, Sikich L, Findling RL, et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. Journal of the American Academy of Child & Adolescent Psychiatry. Aug 2007;46(8):969–978. | 4 |
31 | Belenkaya D. Open comparative randomized study efficacy and tolerability of risperidone, olanzapine, and quetiapine in acute mania [abstract]. European Neuropsychopharmacology. 2005;15(Suppl 2):S130. | 5 |
32 | Casey DE. Implications of the CATIE Trial on Treatment: Extrapyramidal Symptoms. CNS Spectrums Vol 11(7,Suppl7) Jul 2006, 25–31. 2006. | 5 |
33 | Ciobanu AM, et al. The treatment of rapid cycling bipolar disorder (RCBD). European Psychiatry. 2007;22(Suppl 1):S250. | 5 |
34 | Kim J, al. e. The comparison of risperidone, olanzapine and quetiapine in the treatment of chronic schizophrenia and schizoaffective disorder [abstract]. European Neuropsychopharmacology. 2004;14(Suppl 3):S245. | 5 |
35 | Reznik I, al e. Quetiapine in recently relapsed patients with schizophrenia: an open-label head-to-head comparative study versus olanzapine [abstract]. European Psychiatry. 2004;19(Suppl 1):178s. | 5 |
36 | Reznik I, al e. Quetiapine (Seroquel) and olanzapine for acute treatment of patients with schizophrenia: an open-label, comparative study [poster]. Paper presented at: The 26th Collegium Interanationale Neuro-Psychpharmacologicum; June 20–24, 2004; Paris, France. | 5 |
37 | Sacchetti E, al e. Comparison of quetiapine, olanzapine, and risperidone in schizophrenia [abstract]. European Neuropsychopharmacology. 2004;14(Suppl 3):S286. | 5 |
38 | Tune LE. Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies. ClinicalTrials.gov. 2005. | 5 |
39 | Volavka J, Nolan KA, Kline L, et al. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. Schizophrenia Research. Jul 1 2005;76(1):127–129. | 5 |
40 | Arranz B, San L, Duenas RM, et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Human Psychopharmacology. Jan 2007;22(1):11–15. | 6 |
41 | Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research Vol 80(1) Dec 2005, 45–53. 2005. | 6 |
42 | Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology. Jun 2006;31(5):577–588. | 6 |
43 | Yatham L, Fallu A, Binder C. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatrica Scandinavica Vol 116(Suppl434) Oct 2007, 50–56. 12/6/2007 2007. | 6 |
44 | Gharabawi G, al. e. A prospective double-blind study of patients with schizophrenia: effects of risperidone, quetiapine, and placebo [poster]. Paper presented at: 56th Institute in Psychiatric Services (IPS); October 6–10, 2004; Atlanta, Georgia. | 8 |
45 | Keks N, al. e. Non-inferiority efficacy trial of risperidone long-acting (RLAI) vs olanzapine tablets (OLA) [poster]. Paper presented at: 13th Biennial Winter Workshop on Schizophrenia; February 4–10, 2006; Davos, Switzerland. | 8 |
46 | Lieberman J, al e. Comparison of atypicals in first-epidsode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone [poster]. European College of Neuropsychopharmacology Congress. October 22–26 2005. | 8 |
Observational studies | ||
47 | Bernardo M, Azanza JR, Rubio-Terres C, Rejas J. Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS). Actas Espanolas de Psiquiatria. Jul–Aug 2007;35(4):259–262. | 1 |
48 | Ascher-Svanum H, al. E. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006;6(8). | 2 |
49 | Ascher-Svanum H, al. E. The Rate, Pattern, and Cost of Use of Antiparkinsonian Agents Among Patients Treated for Schizophrenia in a Managed Care Setting. American Journal of Managed Care. 2004;9:20–24. | 2 |
50 | Atasoy N, Erdogan A, Yalug I, et al. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Progress in Neuro-Psychopharmacology & Biological Psychiatry. Aug 15 2007;31(6):1255–1260. | 2 |
51 | Bitter I, al. E. Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients. International Clinical Psychopharmacology Jan 2005;20:19–21. | 2 |
52 | Chang JS, Ha K-S, Young Lee K, Sik Kim Y, Min Ahn Y. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. Journal of Clinical Psychiatry. Mar 2006;67(3):461–467. | 2 |
53 | Gianfrancesco, Pesa J, Wang R. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, quetiapine. Journal of Managed Care Pharmacy. 2005;11(3):220–230. | 2 |
54 | Haupt DW, Fahnestock PA, Flavin KA, et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology. 2007:1–9. | 2 |
55 | Kaddurah-Daouk R, McEvoy J, Baillie R, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Molecular Psychiatry Vol 12(10) Oct 2007, 934–945. 2007. | 2 |
56 | Kim J-H, Kim S-Y, Ahn YM, Kim YS. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry Vol 30(2) Mar 2006, 301–305. 2006. | 2 |
57 | Park S, Ross-Degnan D, Adams AS, Sabin J, Kanavos P, Soumerai SB. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: Population-based study. British Journal of Psychiatry Vol 187(2) Aug 2005, 137–142. 2005. | 2 |
58 | Ren X, al. E. Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. Journal of Clinical Pharmacy & Therapeutics. Feb 2005;30:65–71 | 2 |
59 | Burns T, Christova L, Cooper S, et al. Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: A naturalistic cohort study. Acta Psychiatrica Scandinavica Vol 113(2) Feb 2006, 126–134. 2006. | 3 |
60 | Kearns AE, Goff DC, Hayden DL, Daniels GH. Risperidone-associated hyperprolactinemia. Endocrine Practice. Nov–Dec 2000;6(6):425–429. | 3 |
61 | Lew KH. The effect of medication adherence on health care utilization in bipolar disorder Manag Care Interface. 2006;19(9):41–46. | 3 |
62 | McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. Journal of Clinical Psychiatry. Apr 2005;66(4):444–449; quiz 546. | 3 |
63 | Patel NC, Crismon ML, Pondrom M. Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic. Journal of Behavioral Health Services & Research. Oct–Dec 2005;32(4):438–445. | 3 |
64 | Reist C, Mintz J, Albers LJ. Second generation antipsychotic exposure and metabolic related disorders in patients with schizophrenia. Journal of Clinical Psychopharmacology. 2007;27(1):46–50. | 3 |
65 | Swanson J, Van Dorn RA, Swartz MS. Effectiveness of atypical antipsychotics for substance use in schizophrenia patients. Schizophrenia Research. 2007;94(1–3):114–118. | 3 |
66 | Swanson JW, Swartz MS, Elbogen EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophrenia Bulletin. 2004;30(1):3–20. | 3 |
67 | Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J, Group SS. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. Journal of Clinical Psychiatry. Sep 2005;66(9):1130–1133. | 3 |
68 | Ward A, Ishak K, Proskorovsky I, Caro J. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clinical Therapeutics. Nov 2006;28(11):1912–1921. | 3 |
69 | Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Services. 2004;55(8):886–891. | 3 |
70 | Carlson C, Hornbuckle K, DeLisle F, Kryzhanovskaya L, Breier A, Cavazzoni P. Diabetes mellitus and antipsychotic treatment in the United Kingdom. European Neuropsychopharmacology. Jul 2006;16(5):366–375. | 4 |
71 | Coley KC, Carter CS, DaPos SV, Maxwell R, Wilson JW, Branch RA. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. Journal of Clinical Psychiatry. Dec 1999;60(12):850–856. | 4 |
72 | Duncan E, Dunlop BW, Boshoven W, Woolson SL, Hamer RM, Phillips LS. Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population. International Clinical Psychopharmacology. Jan 2007;22(1):1–11. | 4 |
73 | Kang B-J, Cho M-J, Oh J-T, Lee Y, Chae B-J, Ko J. Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS? Human Psychopharmacology. Aug 2006;21(6):387–391. | 4 |
74 | Lambert MT, Copeland LA, Sampson N, Duffy SA. New-onset type-2 diabetes associated with atypical antipsychotic medications. Progress in Neuro-Psychopharmacology & Biological Psychiatry. Jul 2006;30(5):919–923. | 4 |
75 | Manchanda R, Norman RM, Malla AK, Manocha R. Antipsychotic use in a first episode psychosis program. International Journal of Psychiatry in Clinical Practice Vol 11(2) Jun 2007, 151–156. 2007. | 4 |
76 | Miller EA, Leslie DL, Rosenheck RA. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. Journal of Nervous & Mental Disease. Jun 2005;193(6):387–395. | 4 |
77 | Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ. Hyperlipidemia following treatment with antipsychotic medications. American Journal of Psychiatry. 2006;163(10):1821–1825. | 4 |
78 | Ostbye T, Curtis LH, Masselink LE, et al. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. Pharmacoepidemiology & Drug Safety. Jun 2005;14(6):407–415. | 4 |
79 | Sacchetti E, Turrina C, Parrinello G, Brignoli O, Stefanini G, Mazzaglia G. Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure. International Clinical Psychopharmacology. Jan 2005;20(1):33–37. | 4 |
80 | Vanelli M, Burstein P, Cramer J. Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. Psychiatric Services. Sep 2001;52(9):1248–1250. | 4 |
81 | Alhamad AM. Schizophrenia relapse in relation to drug treatment. Neurosciences. 2005;10(1):68–72. | 5 |
82 | Baker R, al e. Efficacy of olanzapine combined with valproate or lithiumin the treatment of dysphoric mania. British Journal of Psychiatry. 2004;185:472–478. | 5 |
83 | Bardenstein L, et al. Aggressive behavior in adolescents: an open-label study with quetiapine. European Psychiatry. 2007;17(Suppl 1):118S–119S. | 5 |
84 | Cohen D, Dekker J, Peen J, Gispen-de Wied C. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. European Neuropsychopharmacology Vol 16(3) Apr 2006, 187–194. 2006. | 5 |
85 | Faries D, al. E. Psychiatric Hospitalizations and Violent Behaviors in the Long-Term Naturalistic Treatment of Patients With Schizophrenia With Olanzapine or Quetiapine Department of Health Outcomes, Eli Lilly. 2005. | 5 |
86 | Gianfrancesco F, Pesa J. Differential risks and associated costs of hospitalization during antipsychotic treatment in Medicaid patients with schizophrenia [poster]. Paper presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 10th Annual Internation Meeting; May 15–18, 2005; Washington, D.C. | 5 |
87 | Hall J, Dodd S, Nelson M. Atypical antipsychotics: treatment patterns, utilization and cost among managed care enrolless [abstract]. Value in Health. 2003;6(3):355. | 5 |
88 | Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) Study: Implications for the Treatment of Schizophrenia. CNS Drugs Vol 20(4) 2006, 293–301. 2006. | 5 |
89 | Knapp M, Windmeijer F, Haro J, al e. 12-month cost-effectivenss analysis of oral antipsychotic treatments in patients with schizophrenia in the Pan-European SOHO (Schizophrenia Outpatient Health Outcome) study [abstract]. Value in Health. 2005;8(6):A204. | 5 |
90 | Rajagopalan K, Lage M. Hospitalization and emergency room visits before and after treatments with atypical antipsychotics [poster]. Paper presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 10th Annual Internation Meeting; May 15–18, 2005; Washington, D.C. | 5 |
91 | Wang P, Zhao Z. Comparison of olanzapine versus quetiapine in the treatment of hospitalized patients with schizophrenia [abstract]. Value in Health. 2003;6(3):355. | 5 |
92 | Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB. Early use of clozapine for poorly responding first-episode psychosis. Journal of Clinical Psychopharmacology Vol 27(4) Aug 2007, 369–373. 2007. | 6 |
93 | Ahn YM, Chang JS, Kim Y, et al. Reduction in hospital stay of chronic schizophrenic patients after long-term clozapine treatment. International Clinical Psychopharmacology Vol 20(3) May 2005, 157–161. 2005. | 6 |
94 | Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. Journal of Clinical Psychiatry. 2006;67(3):453–460. | 6 |
95 | Blader JC. Pharmacotherapy and postdischarge outcomes of child inpatients admitted for aggressive behavior. Journal of Clinical Psychopharmacology. 2006;26(4):419–425. | 6 |
96 | Ciudad A, Gutierrez M, Canas F, et al. Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study. Progress in neuro-psychopharmacology & biological psychiatry. Jul 2005;29(6):944–951. | 6 |
97 | Czekalla J, Dittmann RW, Holstein W, Wagner T, Langer F, Linden M. Olanzapine (ZyprexaReg.) Treatment in Patients Pre-treated with other Antipsychotics: Pharmacovigilance Data from a Large Drug Utilization Observation (DUO) Study in Germany. German Journal of Psychiatry Vol 8(3) 2005, 49–58. 2005. | 6 |
98 | de Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophrenia Research. 2007;92:95–102. | 6 |
99 | Edell WS, Tunis SL. Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients. American Journal of Geriatric Psychiatry. 2001;9(3):289–297. | 6 |
100 | Feroz-Nainar C, Roy M. Risperidone and late onset tics. Autism. May 2006;10(3):302–307. | 6 |
101 | Findling RL, Reed M, O'Riordan M, Demeter CA, et al. Effectiveness, Safety, and Pharmacokinetics of Quetiapine in Aggressive Children With Conduct Disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(7):792–800. | 6 |
102 | Ganesan S, Agambaram V, Randeree F, et al. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Current Medical Research & Opinion. 2008;24(1):21–32. | 6 |
103 | Ghaemi SN, Hsu DJ, Rosenquist KJ, Pardo TB, Goodwin FK. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry. Mar 2006;30(2):209–213. | 6 |
104 | Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study. BMJ: British Medical Journal Vol 330(7489) Feb 2005, 1–6. 2005. | 6 |
105 | Guha P, Roy K, Sanyal D, Dasgupta T, Bhattacharya K. Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics. J Indian Med Assoc. Dec 2005;103(12):660–664. | 6 |
106 | Han C, Lee B-H, Kim Y-K, et al. Satisfaction of patients and caregivers with long-acting injectable risperidone and oral atypical antipsychotics. Primary Care & Community Psychiatry Vol 10(3) 2005, 119–124. 2005. | 6 |
107 | Hardy TA, Marquez E, Kryzhanovskaya L, Taylor CC, Cavazzoni P. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. Journal of Clinical Psychopharmacology. 2006;26(4):405–408. | 6 |
108 | Henderson DC, Copeland PM, Borba CP, et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Journal of Clinical Psychiatry. May 2006;67(5):789–797. | 6 |
109 | Kasper S, Brecher M, Fitton M, al. e. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. International Clinical Psychopharmacology. 2004;19(5):281–289. | 6 |
110 | Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. Journal of Child & Adolescent Psychopharmacology. 1998;8(3):151–159. | 6 |
111 | Kronenberger WG, et al. Quetiapine Addition in Methylphenidate Treatment-Resistant Adolescents with Comorbid Attention-Deficit/Hyperactivity Disorder, Conduct/Oppositional-Defiant Disorder, and Aggression: A Prospective, Open-Label Study. journal of Child & Adolescent Psychopharmacology. 2007;17(3):334–347. | 6 |
112 | Kurz A, Schwalen S, Schmitt A. Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice. International Psychogeriatrics Vol 17(4) Dec 2005, 605–616. 2005. | 6 |
113 | Lasser R, al. e. Optimization of long-acting risperidone for maintenance therapy in schizophrenia [poster]. Paper presented at: International Congress of Schizophrenia research; April 3–6, 2005; Savannah, Georgia. | 6 |
114 | Lee PE, Sykora K, Gill SS, et al. Antipsychotic Medications and Drug-Induced Movement Disorders Other Than Parkinsonism: A Population-Based Cohort Study in Older Adults. Journal of the American Geriatrics Society Vol 53(8) Aug 2005, 1374–1379. 2005. | 6 |
115 | McGrath BM, Tempier R. Patients' Opinions of Olanzapine and Risperidone Following Long-term Treatment: Results from a Cross-sectional Survey. Pharmacopsychiatry Vol 38(4) Jul 2005, 147–157. 2005. | 6 |
116 | Micca JL, Hoffmann VP, Lipkovich I, Ahl J, Baker RW, Hardy TA. Retrospective Analysis of Diabetes Risk in Elderly Patients With Dementia in Olanzapine Clinical Trials. American Journal of Geriatric Psychiatry Vol 14(1) Jan 2006, 62–70. 2006. | 6 |
117 | Moeller KE, Shireman TI, Liskow BI. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. Journal of Clinical Psychiatry. Dec 2006;67(12):1942–1947. | 6 |
118 | Nonino F, De Girolamo G, Gamberini L, Goldoni CA, Modena Work Group for Antipsychotics in D. Survival among elderly Italian patients with dementia treated with atypical antipsychotics: observational study. Neurological Sciences. Dec 2006;27(6):375–380. | 6 |
119 | Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-Term Use of Risperidone in Children with Disruptive Behavior Disorders and Subaverage Intelligence: Efficacy, Safety, and Tolerability. Journal of Child and Adolescent Psychopharmacology Vol 16(3) Jun 2006, 260–272. 2006. | 6 |
120 | Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ Canadian Medical Association Journal. Feb 27 2007;176(5):627–632. | 6 |
121 | Staller J. The effect of long-term antipsychotic treatment on prolactin. Journal of Child & Adolescent Psychopharmacology. Jun 2006;16(3):317–326. | 6 |
122 | Treuer T, Anders M, Bitter I, et al. Effectiveness and tolerability of schizophrenia treatment in Central and Eastern Europe: Results after 1 year from a prospective, observational study (IC-SOHO). International Journal of Psychiatry in Clinical Practice Vol 10(2) Jun 2006, 78–90. 2006. | 6 |
123 | Wehmeier PM, Kluge M, Schneider E, Schacht A, Wagner T, Schreiber W. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. Apr 13 2007;31(3):703–712. | 6 |
124 | Bai Y-M, Yu S-C, Chen J-Y, Lin C-Y, Chou P, Lin C-C. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. International Clinical Psychopharmacology. Mar 2005;20(2):79–85. | 7 |
125 | Gaszner P, Makkos Z. Clozapine maintenance therapy in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry. May 2004;28(3):465–469. | 7 |
126 | Gianfrancesco F, Wang RH, Pesa JA. Relationship between initial quetiapine dose and effectiveness and reflected in subsequent mental health service use among patients with schizophrenia or bipolar disorder. Value in Health. 2005;7(3):269–270. | 7 |
127 | Goldberg JF, Kelley ME, Rosenquist KJ, Hsu DJ, Filkowski MM, Ghaemi SN. Effectiveness of quetiapine in rapid cycling bipolar disorder: a preliminary study. Journal of Affective Disorders. 2008;105:305–310. | 7 |
128 | Graham KA, Perkins DO, Edwards LJ, Barrier RC, Jr., Lieberman JA, Harp JB. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. American Journal of Psychiatry. Jan 2005;162(1):118–123. | 7 |
129 | Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, Herbison P. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Safety. 2007;30(7):569–579. | 7 |
130 | Hellewell JS. Quetiapine demonstrates good tolerability and is associated with improvements with extrapyramidal symptoms in patients with schizophrenia switched from other antipsychotics:results of a naturalistic study. International Journal of Psychiatry in Clinical Practice. 2006;67(3):355–362. | 7 |
131 | Kinon B, Ahl J, al. E. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia [erratum]. International Journal of Neuropsychopharmacology. 2003;6(3):313. | 7 |
132 | Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. Journal of Clinical Psychopharmacology. 2005;25(3):255–258. | 7 |
133 | Lynch J, Morrison J, Graves N, al e. The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia. European Psychiatry. 2001;16:307–312. | 7 |
134 | Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clinical Therapeutics. Dec 2005;27(12):1930–1941. | 7 |
135 | Modestin J, Dal Pian D, Agarwalla P. Clozapine diminishes suicidal behavior: a retrospective evaluation of clinical records. Journal of Clinical Psychiatry. 2005;66(4):534–538. | 7 |
136 | Nasrallah H, Loebel A, Murray S. Lipid profile pre and post treatment in ziprasidone clinical trials [poster]. 157th Annual Meeting of the American Psychiatric Association. May 1–6 2004. | 7 |
137 | Pajonk F-G, Schreiner A, Peters S, Rettig K, Degner D, Ruther E. Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia.[erratum appears in J Clin Psychopharmacol. 2006 Feb;26(1):26]. Journal of Clinical Psychopharmacology. Aug 2005;25(4):293–300. | 7 |
138 | Sharma V, Smith A, Mazmanian D. Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder. Bipolar Disorders Vol 8(4) Aug 2006, 400–404. 2006. | 7 |
139 | Smelson DA, Tunis SL, Nyhuis AW, Faries DE, Kinon BJ, Ascher-Svanum H. Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. Journal of Clinical Psychopharmacology. 2006;26(6):666–667. | 7 |
Placebo controlled trials | ||
140 | Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. New England Journal of Medicine. Feb 2 2006;354(5):472–482. | 2 |
141 | Troost PW, Althaus M, Lahuis BE, Buitelaar JK, Minderaa RB, Hoekstra PJ. Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study. Journal of Child & Adolescent Psychopharmacology. Oct 2006;16(5):561–573. | 2 |
142 | Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain. Journal of Clinical Psychiatry. 2008:e1–e6. | 3 |
143 | Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. American Journal of Psychiatry. Dec 2006;163(12):2072–2079. | 3 |
144 | Wu R-R, Zhao J-P, Jin H, Shao P, Fang M-S, Guo X-F. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain. Journal of American Medical Association. 2008;299(2):185–193. | 3 |
145 | Kurlan R, Cummings J, Raman R, Thal L, Alzheimer's Disease Cooperative Study G. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. Apr 24 2007;68(17):1356–1363. | 4 |
146 | Parkinson Study G. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999;340:757–763. | 4 |
147 | Holmes C, Wilkinson D, Dean C, et al. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: A randomised double blind placebo controlled study. International Journal of Geriatric Psychiatry Vol 22(4) Apr 2007, 380–381. 2007. | 5 |
148 | Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. A 6-week placebo-controlled study on the safety and tolerability of flexible doses of oral paliperidone extended-release tablets in the treatment of schizophrenia in elderly patients [poster]. 159th Annual Meeting of the American Psychiatric Association. May 20–25, 2006 2006:Poster NR441. | 5 |
149 | McIntyre RS, Kennedy SH, Carlson B, et al. Aripiprazole for relapse prevention in bipolar disorder: a 100-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2006;31 (Suppl 1s):S229. | 5 |
150 | Paleacu D, Doron M, Mirecky I, Barak Y. Quetiapine in Alzheimer's disease patients with behavioral and psychotic symptoms of dementia-a six weeks double blind placebo controlled study. Paper presented at: 12th Congress of the International Psychogeriatic Association, 2005. | 5 |
- Appendix F. Excluded Studies - Drug Class Review: Atypical Antipsychotic DrugsAppendix F. Excluded Studies - Drug Class Review: Atypical Antipsychotic Drugs
Your browsing activity is empty.
Activity recording is turned off.
See more...